Silence Therapeutics is led by a strong senior management team with a proven track record in drug development and successful team leadership.


Chief Executive

Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and became chief executive in May 2013. He engineered two fundraisings last year to raise £11m for the company and spearheaded the £19m placing completed in April 2013.

He has over 17 years of in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology/biotech ventures.


Finance Director and Company Secretary

Tim joined the company in August 2012 and became full time in October. Previously he was head of research at Xcap Securities and an analyst at Evolution Securities. After qualifying as a chartered accountant he left practice to become a journalist. For 12 years he worked in the Daily Mail City Office covering biotech, electronics and real estate. Tim gained a BA in Philosophy at University College London.


Chief Scientific Officer

Dr. Kaufmann possesses more than 14 years of biotechnology industry experience in both the United States and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies at the Company’s Berlin location. Prior to joining Silence, Dr. Kaufmann was a senior scientist at Chiron Corporation, where he was responsible for leading one of the company’s molecular biology research groups focused on breast cancer.

From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg, Germany. Dr. Kaufmann was a postdoctoral fellow at the Howard Hughes Medical Institute, University of California, Los Angeles and received his Ph.D. in molecular biology from the Philipps University Marburg.


Director and Chief Medical Officer

Dr Michael Khan is the former Head of Molecular Medicine at the University of Warwick and a consultant physician and the Director of the Lipid and Coronary Prevention Clinics for Warwickshire. He is an expert advisor to the UK Clinical Guidelines Development Group and The National Institute for Clinical Excellence (NICE). He has served on numerous advisory boards for Pharmaceutical companies.

He is a highly cited researcher and experienced clinician with a long track record in metabolic medicine and cancer biology research as well as in the running of clinical trials. He has written several books on diabetes, cholesterol problems and cancer biology and teaches postgraduates and undergraduates in medicine and biological sciences in these areas. He and co-workers have made important contributions to further the understanding of cancer cell biology and diabetes and are working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools. He is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART UK and Diabetes UK and has acted as an expert adviser to numerous national and international organisations in both the public and private sectors.